Skip to Content
Interactive Textbook on Clinical Symptom Research Logo


Home Button

Somatization and Symptoms Evaluation
Author Bios
Introduction
Defining Somatization
Detecting Symptoms
Dimensions of Symptoms
Measuring Symptoms
Psychiatric Comorbidity
Interpreting Symptom Measures
Functional Syndromes and Symptoms
Etiology of Symptoms
Levels of Etiological Certainty
Strengthening Etiological Classification
Confounding Etiological Factors
Symptoms and Patient Expectations
Interpreting Patient Responses
Measuring Multiple Symptoms
Global Rating of Change
Currently selected section: Measuring Somatization
Measuring Other Domains
Conclusions


Chapter 16: Somatization and Symptoms Evaluation: Measuring Somatization
        

The distinction between measuring symptoms and somatization is somewhat arbitrary. Again, symptoms are a manifestation of many defined diseases, whereas somatization defines that subset of patients who experience and report medically unexplained symptoms. There is no "gold standard" measure for somatization.

The American Psychiatric Association's Diagnostic and Statistical Manual, 3rd Edition, Revised (DSM-III-R) provided a list of over 35 somatic symptoms to serve as a checklist for somatoform disorders (i.e. diagnoses consisting of medically unexplained symptoms attributable to psychological factors). Symptoms could count, however, if they had been bothersome any time during a patient's lifetime.

The Diagnostic Interview (DIS) and its successor, the Comprehensive International Diagnostic Interview (CIDI) have a long somatoform module that incorporate the DSM symptom checklist. Inquiring about such a long checklist of symptoms, probing to determine whether each symptom endorsed may have been medically unexplained, and requiring the patient to draw upon lifetime symptom recall has found to be problematic in terms of both efficiency as well as reliability.

Because of this, shorter symptom screeners have been proposed (Derogatis et al.,1974; Othmer and DeSouza,1985; Swartz et al.,1986; Tacchini et al.,1994). A comparison of several of these screeners along with the PHQ-15 is shown in Table 17.1 below.

Table17.1: Comparison of PHQ-15 with other Somatization Screening Measures *
Characteristic PHQ-15 WHO SSD SCL-12 Swartz Othmer
Number of symptoms 15 12 12 11 7
Time Frame of Symptoms 1 month 6 month 1 week Lifetime Lifetime
Symptoms included †
Joint or limb pain
X
"X"
X
X
X
Dizziness
X
X
1/2
X
Fatigue
X
X
X
Headaches
X
X
X
Back pain
X
X
X
Abdominal pain
X
X
X
Chest pain
X
X
X
Breathing trouble
X
X
X
Fainting
X
1/2
X
Gas or indigestion
1/2
X
X
Sleeping trouble
X
X
Palpitations
X
X
Menstrual problems
X
Diarrhea (constipation)
X
X
Sexual pain/problems
X
X
Vomiting
X
X
Numbness or tingling
X
X
Weakness
X
X
Lump in throat
X
Nausea
1/2
X
Heavy- or light-headed
X
Dry mouth
X
Heaviness arms/legs
X
Hot or cold spells
X
Feeling sickly
X
Amnesia
X

* WHO-SSD indicates World Health Organization Schedule for Somatoform Disorders screener; SCL-12 indicates Hopkins Symptom Checklist somatization scale; Swartz and Othmer represent 11-item and 7-item screeners, respectively, for somatization disorder

† X indicates that this symptom (or equivalent) is included on the scale; 1/2 indicates that the two symptoms so designated constitute a single item for the scale; "X" indicates that a symptom close in type to that in the table is represented on the scale


Page 22 of 26
Previous Section